In today's age of information, your customers know that bioavailability is more than just a buzzword. And when it comes to minerals like calcium, magnesium, and iron, we know that no matter how much we take, if the body can't chelate the minerals into amino acids, our ship is sunk.
Albion was founded with mission of making trace nutrients more bioavailable. Since 1956 Albion has had the foresight to do the chelation first and to give the body exactly what it needs for optimal function and health.
"Albion is the only chelate company that backs its ingredients with clinical research—over 85 published human clinical studies; more than 200 scientific studies in animals and humans that establish safety, efficacy, tolerability, and formulation compatibility," said Max Motoyka, director of Albion's Human Products Division. When it comes to chelated minerals, process is everything. In order for the mineral to be optimally bioavailable, the inorganic mineral must be fully reacted to form an organic amino acid that the human body can readily absorb. Not all chelation processes are created equal. Albion uses spray drying of a liquid formation. It's an expensive process, but it produces a highly controlled precise product. "The product is 'flash dried' at a specific moment in the reaction process yielding a 'fully reacted' end product with a guaranteed mineral content range," according to Albion's highly informative website.
Motoyka explained that "every lot of Albion chelates has to pass the FT-IR [Fourier Transform Infrared Spectroscopy] structural bonding finger print test," to ensure all chelates are indeed organic in composition. Furthermore, "Albion is the only chelate manufacturer to receive CAS Numbers on its chelates." The CAS Registry houses information on more that 63 million organic and inorganic substances going as far back as the early 1900s.
Albion's emphasis on research and quality assurance no doubt explains why the company has received EFSA approval on its bisglycinate chelates as well as why the company protects its products and processes with over 150 patents.
On the horizon
Motoyka said that research and development is constantly working toward the next new item, but that it takes time to do it right. "We intend on introductions [in the coming year], but until we are satisfied with our new items, we stay mum," he said.
That said, Albion has at least three new clinical studies teed up for 2012. But Motoyka explained, "our chief business goal is to continue our global expansion efforts. This will require our investing in the needs of several new dossiers for applying to get additional product registrations, especially in the EU." And Albion's track record shows that they know how to navigate EFSA, so if you're looking for a good example of how that's done, look no further.